A 12 week, randomised, double blind study evaluating the effects of low-dose (10 mg) and high-dose (80 mg) atorvastatin on macrophage activity and carotid plaque inflammation as determined by ultra small super-paramagnetic iron oxide (USPIO) enhanced carotid magnetic resonance imaging (MRI).

Trial Profile

A 12 week, randomised, double blind study evaluating the effects of low-dose (10 mg) and high-dose (80 mg) atorvastatin on macrophage activity and carotid plaque inflammation as determined by ultra small super-paramagnetic iron oxide (USPIO) enhanced carotid magnetic resonance imaging (MRI).

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2015

At a glance

  • Drugs Atorvastatin (Primary)
  • Indications Atherosclerosis
  • Focus Biomarker; Therapeutic Use
  • Acronyms ATHEROMA
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 03 Feb 2012 Results of the MRI analysis (n=26) presented at the 37th International Stroke Conference.
    • 02 Jun 2009 Results were published in the Journal of the American College of Cardiology.
    • 21 Apr 2008 The expected completion date for this trial is now 1 Aug 2007.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top